Redesign Science utilizes its NUVO™ technology platform, which combines physics-based molecular dynamics and generative AI, to develop first-in-class small molecule Targeted Protein Interaction Modulators (TPIM™). The company targets the structural protein interactome to enhance control over cellular biology, addressing the complexities of early-stage drug discovery.
Funding
$17M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AC+5Founders
Product
Problem
Traditional drug discovery methods often struggle to address the complexities of protein interactions, limiting the development of effective therapies for diseases involving intricate biological pathways. Targeting protein-protein interactions with small molecules is challenging due to the dynamic and often transient nature of these interactions.
Solution
Redesign Science leverages its NUVO™ technology platform, integrating physics-based molecular dynamics simulations with generative AI, to design first-in-class small molecule Targeted Protein Interaction Modulators (TPIM™). By simulating biomolecular systems at the atomic level, the platform aims to enhance control over cellular biology by targeting the structural protein interactome. This approach facilitates the development of novel therapeutics that can modulate protein interactions with greater precision and efficacy. The NUVO™ platform tackles the challenges of early-stage drug discovery by providing a dynamic, structure-based approach.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapeutics for diseases involving complex protein interactions.
Features
- NUVO™ technology platform combining physics-based molecular dynamics and generative AI.
- Development of first-in-class small molecule Targeted Protein Interaction Modulators (TPIM™).
- Physics-based atomic-level molecular dynamics simulations.
- Targeting the structural protein interactome.
- Integrated physics, chemistry, and synthetic data platform.